Zepbound and Ozempic are two distinct medications often discussed in relation to weight loss, though they have different primary FDA approvals and mechanisms of action. Understanding their differences and similarities is crucial for individuals considering either treatment in consultation with their healthcare provider.

A key differentiator is their FDA approval status. Zepbound is specifically approved for weight loss in adults with a body mass index (BMI) of 30 or more, or a BMI of 27 with at least one weight-related health condition. It also received approval in December 2024 for the treatment of obstructive sleep apnea. In contrast, Ozempic was initially approved in 2017 to treat type 2 diabetes, with later expansions to include the reduction of major cardiovascular events risk and, in 2025, to prevent the worsening of kidney disease. While Ozempic can lead to weight loss, this is considered an off-label use.

Regarding effectiveness for weight loss, Zepbound generally shows greater results. A 72-week study found that individuals taking Zepbound lost an average of 21% of their body weight. For those with sleep apnea, up to 50% experienced no symptoms after one year of treatment. Ozempic, in a 68-week study, led to an average weight loss of 15% of body weight. The medications also differ in their mechanisms: Zepbound is a dual-agonist drug, while Ozempic is a single-agonist. Furthermore, Zepbound is administered via a single-use injection pen, whereas Ozempic uses a multi-dose injection pen. Serious adverse events were reported in 5% to 7% of people taking Zepbound, compared to 3% of those taking Ozempic.

Despite their differences, Zepbound and Ozempic share several important similarities. Both are approved for adults aged 18 and older and are intended for long-term use. They both work by reducing appetite, causing weight loss, lowering blood sugar, and impacting digestion, and are injected once a week. Crucially, both medications carry a boxed warning from the FDA concerning thyroid tumors in animals, though it's unknown if this risk extends to humans. Consequently, both drugs should be avoided if an individual or a family member has a history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2).

Common side effects for both Zepbound and Ozempic include nausea, diarrhea, constipation, vomiting, stomach pain, injection site reactions, burping, and reflux. Zepbound may also cause hair loss and fatigue. More serious, but rarer, side effects for both can include allergic reactions, pancreatitis, and thyroid cancer. Ozempic also lists diabetic retinopathy as a serious side effect, while Zepbound lists gallbladder problems.

The choice between Zepbound and Ozempic should be made in consultation with a healthcare provider, who will consider individual medical conditions, tolerance to side effects, insurance coverage, and specific weight-loss goals. For instance, if heart-related conditions are a primary concern, Ozempic might be recommended due to its proven benefits in reducing cardiovascular event risks in type 2 diabetes patients. Conversely, if the main objectives are significant weight loss or treatment for obstructive sleep apnea, Zepbound might be the preferred option. Insurance coverage can also play a role; since Ozempic is not FDA-approved for weight loss, it might not be covered by insurance for that purpose, potentially making Zepbound a more cost-effective choice for obesity treatment. It is imperative to always consult with a healthcare professional and avoid obtaining medications from unverified online sources due to significant safety risks.